Dextromethorphan Added on for Children With Chronic Irritability

Status Enrolling by invitation

Clinical Trial Summary

Clinical Trial Description

Objectives: It is known that the etiology and mechanism of neuropsychiatric diseases may be related to nerve inflammation. It has been found that dextromethorphan (DM) is an active ingredient in cough-remedies, which can protect neurons in glial cell cultures in the rat brain from inflammatory substances. Although the mechanism of DM is still unknown, it may be related to the regulation of immune dysfunction. Therefore the purpose of this present study was to investigate the adjuvant treatment with DM in the children and adolescents with chronic irritability. Methods: This randomized double-blind clinical trial will evaluate 120 outpatients, aged between 7 and 17 years, with chronic irritability. The study subjects will be randomly assigned into one of the two groups: receiving routine medicine plus DM or routine medicine plus placebo for 8 weeks. Assessments comprising the parents' reported Mood Disorder Questionnaire (MDQ), Affective Reactivity Index (ARI), the Chinese version of the Child Behavior Checklist (CBCL-C) scale, the Swanson, Nolan and Pelham Questionnaire (SNAP-IV), the Sleep Disturbance Scale for Children (SDSC), Problematic smartphone use (PSU) and Checklist for Autism Spectrum Disorder-Chinese Version (CASD-C). Comparison will be done between groups at baseline and at 8 weeks before-and-after the treatment. ;

Study Design

Related Conditions & MeSH terms

Irritable Mood

Clinical Trial Details

NCT number	NCT05043805
Study type	Interventional
Source	Tri-Service General Hospital
Contact
Status	Enrolling by invitation
Phase	Phase 4
Start date	May 9, 2021
Completion date	June 30, 2024

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06133231` - Optimizing Research With Diverse Families	N/A
Completed	`NCT03697837` - Digital Parent Training for Disruptive Behaviors in Children	N/A
Completed	`NCT04776304` - Art Therapy qEEG Study for Service Members With a Traumatic Brain Injury and Posttraumatic Stress Symptoms	N/A
Recruiting	`NCT01326663` - Divalproex Sodium for Mood Swings and Alcohol Use Following Head Injury.	N/A
Completed	`NCT03592368` - Hostile Interpretation Bias Training to Treat Irritability	N/A
Enrolling by invitation	`NCT04635618` - Psychotherapy Strategies for the Treatment of Professionals and Students From Essential Services With High Levels of Emotional Distress in the Context of COVID-19	N/A
Completed	`NCT02507284` - Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease	Phase 2
Completed	`NCT00627250` - Utility of Amantadine Hydrochloride in the Treatment of Post-traumatic Irritability	N/A
Recruiting	`NCT05388656` - Estrogen Variability and Irritability During the Menopause Transition	Phase 4
Active, not recruiting	`NCT05260398` - Examining the Impacts on In-School Behaviors of In-Home Videogame Play	N/A
Terminated	`NCT03863288` - Dose Response Relationship of Oxytocin on Irritability in Youths	Phase 1/Phase 2
Completed	`NCT04715932` - Study of Hesperidin Therapy on COVID-19 Symptoms (HESPERIDIN)	Phase 2
Recruiting	`NCT05414708` - Art Therapy and Emotional Well Being in Military Populations With Posttraumatic Stress Symptoms	N/A
Not yet recruiting	`NCT06020261` - Parent Management Training to Treat Irritability	N/A
Recruiting	`NCT05528926` - RESist Against Irritability Superiority Trial	N/A
Completed	`NCT05974241` - Irritability in Children With ADHD and Emotion Dysregulation	Phase 4
Terminated	`NCT01675960` - Effectiveness of Gabapentin on Chronic Irritability in Neurologically Impaired Children	Phase 2
Recruiting	`NCT05930886` - Focus Groups in Ethnically and Racially Diverse Families